Institut Curie - 1st patient for a clinical trial

The Institut Curie and the biotech company Onxeo have announced the inclusion of the first patient in a clinical trial evaluating a promising molecule that thwarts resistance to treatment in high-grade gliomas in young patients. The clinical validation of this innovative therapy, developed in the laboratories of the Institut Curie, represents a major hope for the fight against these high-risk pediatric cancers.

This Phase 1b/2 study, whose protocol was designed by the Institut Curie in cooperation with Onxeo, benefits from a grant from the European Fight Kids Cancer program, a joint initiative of the French association Imagine for Margo, the Belgian KickCancer Foundation and the Luxembourgish Kriibskrank Kanner Foundation.